Angiotensin II Receptor Antagonists
ApprovedSmall molecule
Angiotensin II Receptor Antagonists is one of 48 small molecule programs targeting Hypoglycemia. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
77 competitors in Hypoglycemia
#DrugCompanyPhaseTrials
1Symlin
AstraZenecaApproved
NOVOLIN R
Novo NordiskApproved
Glucagon
XXeris Pharmaceuticals
Phase 3
Ilaris
NovartisPhase 3
Zegalogue
Zealand PharmaPhase 3
Jardiance
Boehringer IngelheimPhase 3
Sandostatin
Sun PharmaPhase 3
Glibenclamide
Novo NordiskPhase 3
MS Contin
Merck & Co.Phase 2
Elavil
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- NNara Medical University